Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Aurora Cannabis

Canopy Growth

HEXO Corp

SNDL Inc.

You could rightly say that money managers chased after the green in the third quarter.

The Industry Billionaires Bought Hand Over Fist in Q3

Tilray stock may keep rising with higher cannabis sales and the prospect of profits. Tilray could rise at least another 50% if it becomes profitable on an adjusted EBITDA basis in Q4.

Tilray Could Rise Another 50% Once It Reaches Profits By Q4

Cronos Group

It was a great month for pot stocks, but these massive moves seem like ill-informed speculation to me.

Why Hexo, Cronos Group, and Tilray Surged as Much as 76.5% in November

Cannabis stocks like CGC, TLRY and ACB stock are all on the move Friday after lawmakers voted on a landmark bill. The post Cannabis Stocks: Why CGC, TLRY and ACB Stock Are Moving Today appeared first on InvestorPlace.

Cannabis Stocks: Why CGC, TLRY and ACB Stock Are Moving Today

Aphria

Arena Pharmaceuticals

GW Pharmaceuticals

OrganiGram Holdings Inc.

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcoming week.

This Week in Cannabis: 6 Stocks Pivoting for Serious Growth

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Schultze Special Purpose Acquisition Corp II

Trulieve Cannabis Corp.

The improving regulatory landscape for marijuana stocks could usher in a boom, particularly for companies focused on the U.S. market. The post 7 Marijuana Stocks Hoping 2021 Brings Federal Legalization appeared first on InvestorPlace.

7 Marijuana Stocks Hoping 2021 Brings Federal Legalization

U.S. legalization euphoria has investors chasing a number of terrible cannabis stocks.

3 Pot Stocks to Avoid Like the Plague in December

Marijuana stocks popped on Wednesday after a United Nations commission voted to remove cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a list that includes heroin and fentanyl.

Pot Stocks Get a Lift After a Symbolic Win From the UN

BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021. Hormosan is primarily focused on pain therapy and neurology and is part of the Lupin Group, an international entity that sells innovative drugs and generics. Ho

Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany

Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?

This stock is prone to leaving investors in the red and unhappy.

1 Risky Cannabis Stock to Avoid

Fastly

Moderna

These stocks could make investors rich next month.

3 Top Breakout Stocks to Watch in December

Amplify Alternative Harvest ETF

Cannabis stocks continued their postelection rise from the ashes Monday, ahead of votes this week regarding decriminalization in the U.S. House of Representatives and the United Nations.

Cannabis Watch: Pot stocks pop ahead of U.S., UN votes on cannabis legalization

As marijuana stocks go, OrganiGram Holdings Inc. (NASDAQ: OGI) is a relatively small player.

Why Marijuana Stocks Posted Big November Gains — and Could Keep Rising

Like other marijuana stocks, Tilray has struggled to rein in losses, while investors gauge the impact of the U.S. election. So, is Tilray stock a buy now?

Is Tilray Stock A Buy Right Now? Here's What Earnings, Charts Show

GrowGeneration Corp

Village Farms International

The Dow passed 30,000 as investors looked forward to 2021.

Stock Markets Are Record-Bound; Marijuana Stocks Soar

Shares of major cannabis stocks are soaring once again following the news that Joe Biden's transition has formally begun. The uptick is fueled by expectations that the incoming administration will loosen regulations, as well as more US states legalizing sales of recreational marijuana.

Cannabis stocks are rising again

Cannabis stocks are soaring higher on Tuesday as investors continue to prepare for a Joe Biden presidency that could benefit pot companies. The post Cannabis Stocks: Why ACB, TLRY, CGC, HEXO and CRON Are Soaring Today appeared first on InvestorPlace.

Cannabis Stocks: Why ACB, TLRY, CGC, HEXO and CRON Are Soaring Today

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that it has entered into privately negotiated exchange agreements with certain holders of its 5.00% Convertible Senior Notes due 2023 (the "Notes"). Pursuant to the exchange agreements, the Company will exchange approximately $72.9 million in aggregate principal amount of Notes plus accrued interest,

Tilray, Inc. Announces Agreement to Exchange an Additional $72.9 Million in Principal Amount of Its 5.00% Convertible Senior Notes Due 2023 for Common Stock

Tilray is at a crossroads. It's currently enjoying strong tailwinds from the broader marijuana rally, but TLRY stock's fundamentals are underwhelming.

Mediocre Q3 Earnings Cut Struggling Tilray Stock off at the Knees

Amplify Seymour Cannabis ETF

Innovative Industrial Properties

Altria

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Constellation Brands

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Stock Selection Matters (Podcast Transcript)

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that it has entered into a privately negotiated exchange agreement with a certain holder of its 5.00% Convertible Senior Notes due 2023 (the "Notes"). Pursuant to the exchange agreement, the Company will exchange approximately $124.3 million in aggregate principal amount of Notes plus accrued interes

Tilray, Inc. Announces Agreement to Exchange Approximately $124.3 Million in Principal Amount of Its 5.00% Convertible Senior Notes Due 2023 for Common Stock

Tilray beat on earnings in their latest results pushing up their stock; Revenues remain flat-to-lower over multiple quarters despite epic increases in Canadian cannabis retail sales.

Tilray: Will Raise Money Diluting Shares Sending Stock Lower

A few months ago, Tilray stock didn't look too hot. But with rising Covid-19 cases, will the narrative shift positively for TLRY?

Coronavirus May Lend a Helping Hand to Tilray Shares

The bullish case for cannabis company Tilray Inc (NASDAQ: TLRY) can no longer be justified after the company's third-quarter earnings report showed stalling momentum in international markets, according to Jefferies. The Tilray Analyst: Owen Bennett downgraded Tilray from Hold to Underperform and lowered the price target from $5.60 to $4.77.

Why Jefferies Is Losing Its Tilray Buzz

News for Tilray Brands Stock (TLRY)